MedCity News November 22, 2024
Frank Vinluan

A patient death in a clinical trial usually prompts the FDA to impose a clinical hold. But Neurogene is able to avoid a lengthy clinical trial pause largely because of its participation in an FDA pilot program intended to speed up the development of therapies for rare diseases.

The clinical trial participant who was hospitalized for severe complications after receiving the high dose of Neurogene’s experimental Rett syndrome gene therapy has died.

Neurogene disclosed the death in a regulatory filing after the market close Thursday. The company said the FDA is permitting the Phase 1/2 study to continue with the low dose of the therapy, code-named NGN-401. Neurogene added that it will incorporate this dose in planning the design of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Patient / Consumer, Pharma / Biotech, Provider, Trends
Christophe Weber, veteran Takeda CEO, to retire next year
FDA warns GLP-1 compounder over safety rules
Metsera, Maze secure combined $415 million in IPOs
Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
From discovery to delivery: Finding an investment edge in biopharma services

Share This Article